Fox SH - Search Results

1

Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Fox SH, Henry B, Hill M, Crossman A, Brotchie J. Fox SH, et al. Mov Disord. 2002 Nov;17(6):1180-7. doi: 10.1002/mds.10289. Mov Disord. 2002. PMID: 12465055

2

Normethylclozapine potentiates the action of quinpirole in the 6-hydroxydopamine lesioned rat.

Fox S, Brotchie J. Fox S, et al. Eur J Pharmacol. 1996 Apr 22;301(1-3):27-30. doi: 10.1016/0014-2999(96)00100-8. Eur J Pharmacol. 1996. PMID: 8773443

3

New treatments for movement disorders?

Fox SH, Brotchie JM. Fox SH, et al. Trends Pharmacol Sci. 1996 Oct;17(10):339-42. doi: 10.1016/s0165-6147(96)30018-7. Trends Pharmacol Sci. 1996. PMID: 8979766 No abstract available.

4

Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

Fox SH, Moser B, Brotchie JM. Fox SH, et al. Exp Neurol. 1998 May;151(1):35-49. doi: 10.1006/exnr.1998.6792. Exp Neurol. 1998. PMID: 9582253

5

Quantitative assessment of dyskinesias in subhuman primates.

Brotchie JM, Fox SH. Brotchie JM, et al. Among authors: fox sh. Mov Disord. 1999;14 Suppl 1:40-7. Mov Disord. 1999. PMID: 10493402 Review. No abstract available.

6

The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.

Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM. Henry B, et al. Among authors: fox sh. Mov Disord. 1999 Sep;14(5):744-53. doi: 10.1002/1531-8257(199909)14:5<744::aid-mds1006>3.0.co;2-7. Mov Disord. 1999. PMID: 10495035

7

5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat.

Fox SH, Brotchie JM. Fox SH, et al. Eur J Pharmacol. 2000 Jun 9;398(1):59-64. doi: 10.1016/s0014-2999(00)00238-7. Eur J Pharmacol. 2000. PMID: 10856448

8

Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.

Nash JE, Fox SH, Henry B, Hill MP, Peggs D, McGuire S, Maneuf Y, Hille C, Brotchie JM, Crossman AR. Nash JE, et al. Among authors: fox sh. Exp Neurol. 2000 Sep;165(1):136-42. doi: 10.1006/exnr.2000.7444. Exp Neurol. 2000. PMID: 10964492

9

5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease.

Fox SH, Brotchie JM. Fox SH, et al. Mov Disord. 2000 Nov;15(6):1064-9. doi: 10.1002/1531-8257(200011)15:6<1064::aid-mds1002>3.0.co;2-c. Mov Disord. 2000. PMID: 11104187

10

Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan.

Fox SH, Henry B, Hill MP, Peggs D, Crossman AR, Brotchie JM. Fox SH, et al. Mov Disord. 2001 Jul;16(4):642-50. doi: 10.1002/mds.1148. Mov Disord. 2001. PMID: 11481687

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

236 results

Search Page

Filters